RYTM Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of -9.67%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Alnylam Pharmaceuticals's return on equity of --.

Rhythm Pharmaceuticals has a consensus price target of $103.64, signalling upside risk potential of 13.35%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $330.77 which suggests that it could grow by 2.47%. Given that Rhythm Pharmaceuticals has higher upside potential than Alnylam Pharmaceuticals, analysts believe Rhythm Pharmaceuticals is more attractive than Alnylam Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.265, which suggesting that the stock is 126.541% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.226, suggesting its less volatile than the S&P 500 by 77.386%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Rhythm Pharmaceuticals's net income of -$49.5M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 41.24x versus 17.67x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Apellis Pharmaceuticals has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of -55.29%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Apellis Pharmaceuticals's return on equity of -96.34%.

Rhythm Pharmaceuticals has a consensus price target of $103.64, signalling upside risk potential of 13.35%. On the other hand Apellis Pharmaceuticals has an analysts' consensus of $35.45 which suggests that it could grow by 79.49%. Given that Apellis Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe Apellis Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.265, which suggesting that the stock is 126.541% more volatile than S&P 500. In comparison Apellis Pharmaceuticals has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.72%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apellis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Apellis Pharmaceuticals pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are smaller than Apellis Pharmaceuticals quarterly revenues of $166.8M. Rhythm Pharmaceuticals's net income of -$49.5M is higher than Apellis Pharmaceuticals's net income of -$92.2M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Apellis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 41.24x versus 3.17x for Apellis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ardelyx has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of -55.52%. Rhythm Pharmaceuticals's return on equity of -116.92% beat Ardelyx's return on equity of -34.68%.

Rhythm Pharmaceuticals has a consensus price target of $103.64, signalling upside risk potential of 13.35%. On the other hand Ardelyx has an analysts' consensus of $10.91 which suggests that it could grow by 137.15%. Given that Ardelyx has higher upside potential than Rhythm Pharmaceuticals, analysts believe Ardelyx is more attractive than Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals has a beta of 2.265, which suggesting that the stock is 126.541% more volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are smaller than Ardelyx quarterly revenues of $74.1M. Rhythm Pharmaceuticals's net income of -$49.5M is lower than Ardelyx's net income of -$41.1M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 41.24x versus 3.01x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -151.35% compared to Rhythm Pharmaceuticals's net margin of 4.19%. Rhythm Pharmaceuticals's return on equity of -116.92% beat TG Therapeutics's return on equity of 19.78%.

Rhythm Pharmaceuticals has a consensus price target of $103.64, signalling upside risk potential of 13.35%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 4.27%. Given that Rhythm Pharmaceuticals has higher upside potential than TG Therapeutics, analysts believe Rhythm Pharmaceuticals is more attractive than TG Therapeutics.

Rhythm Pharmaceuticals has a beta of 2.265, which suggesting that the stock is 126.541% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Rhythm Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals quarterly revenues are $32.7M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Rhythm Pharmaceuticals's net income of -$49.5M is lower than TG Therapeutics's net income of $5.1M. Notably, Rhythm Pharmaceuticals's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 161.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals is 41.24x versus 16.16x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.